Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States

References

• Rajkumar SV. Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases [Internet]. UpToDate; 2018 [cited 21, 2018]. Available from: https://www.uptodate.com/contents/pathogenesis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases. Accessed 256 2019
   Google Scholar
• Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–1822.1558973
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325. doi:10.1038/leu.2012.10022475872
   PubMed Web of Science ®Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–5130. doi:10.1182/blood-2013-01-45300123670179
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32(10):920–928. doi:10.1007/s12325-015-0250-026498944
   PubMed Web of Science ®Google Scholar
• Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053. doi:10.1182/bloodadvances.201701064529748430
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–2060. doi:10.1161/CIRCULATIONAHA.104.48918716186440
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004;63(1):129–138. doi:10.1212/01.WNL.0000132966.36437.1215249622
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.7878478
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–219. doi:10.1080/13506129.2018.154982530614283
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2): e000364–e000364. doi:10.1161/JAHA.111.000364
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119. doi:10.1182/blood-2016-11-75162828126928
   PubMed Web of Science ®Google Scholar
• Reich G, Held T, Siegert W, Kampf D, Dörken B, Maschmeyer G. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2001;27(3):341–343. doi:10.1038/sj.bmt.170276611277185
   PubMedGoogle Scholar
• Weiss BM, Lund SH, Bjorkholm M, et al. Improved survival in AL amyloidosis: a population-based study on 1,430 patients diagnosed in Sweden 1995–2013. Blood. 2016;128(22):4448. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015;278(2):126–144. doi:10.1111/joim.2015.278.issue-226077367
   PubMedGoogle Scholar
• Rosenzweig M, Giralt S, Landau H. Light-chain amyloidosis: SCT, novel agents and beyond. Bone Marrow Transplant. 2013;48(8):1022–1027. doi:10.1038/bmt.2012.19923103675
   PubMedGoogle Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi:10.1056/NEJMoa180568930145929
   PubMed Web of Science ®Google Scholar
• Quarta CC, Solomon SD. Stabilizing transthyretin to treat ATTR cardiomyopathy. N Engl J Med. 2018;379(11):1083–1084. doi:10.1056/NEJMe181007430145933
   PubMedGoogle Scholar
• European Medicines Agency. Onpattro Summary of Product Characteristics.Amsterdam: European Medicines Agency; 2019.
   Google Scholar
• Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–540. doi:10.1016/j.acvd.2013.06.05124070600
   PubMed Web of Science ®Google Scholar
• Lin HM, Gao X, Cooke CE, et al. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017;33(6):1017–1031. doi:10.1080/03007995.2017.130190328277869
   PubMed Web of Science ®Google Scholar
• Health Forum, LLC. Fast facts on U.S. hospitals, 2018 [Internet]. American Hospital Association – Data Insights – Statistics; 2018 [cited 320, 2018]. Available from: https://www.aha.org/statistics/fast-facts-us-hospitals.
   Google Scholar
• Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia [Internet]; 2018 Available from http://www.nature.com/articles/s41375-018-0060-x. Accessed April 12, 2018. doi:10.1038/s41375-018-0060-x
   Web of Science ®Google Scholar
• Lee M-H, Lee S-P, Kim Y-J, Sohn D-W. Incidence, diagnosis and prognosis of cardiac amyloidosis. Korean Circ J. 2013;43(11):752. doi:10.4070/kcj.2013.43.11.75224363751
   PubMedGoogle Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212. doi:10.1161/CIRCULATIONAHA.108.84333419752327
   PubMed Web of Science ®Google Scholar
• Boccuti C, Casillas G. Aiming for Fewer Hospital U-turns: The Medicare Hospital Readmission Reduction Program [internet]. Washington, DC: The Henry J. Kaiser Family Foundation; 2017 3 Available from: https://www.kff.org/report-section/aiming-for-fewer-hospital-u-turns-the-medicare-hospital-readmission-reduction-program-issue-brief/#endnote_link_211172-5. Accessed 2018 320.
   Google Scholar
• Premier Applied Sciences. Premier Healthcare Database: Data that Informs and Performs. Charlotte, NC: Premier Inc.; 2018 2.
   Google Scholar